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Abstract
Background: Immune check point inhibitors (ICIs) have emerged as a new therapeutic paradigm for a variety of
malignancies including metastatic melanoma. As the use of ICIs expand, immune-mediated adverse events are
becoming a common occurrence.
Case presentation: We describe the first reported patient with small vessel vasculitis, manifested by digital ischemia,
following treatment with high dose Ipilimumab for resected stage IIIB/C melanoma. This patient received high dose
steroids, five-day intravenous (IV) Epoprostenol protocol, botulinum toxin injections, and Rituximab 375 mg/m2 weekly
for four cycles. With this treatment regimen, the digital ischemia did not progress proximally, but she did require
multiple distal digit amputations about six months after the onset of her symptoms.
Conclusions: Prompt identification and management of immune related adverse events (IRAEs) are critical to optimal
patient management. This patient’s vasculitis did not reverse, but was likely halted and stabilized with multiple
immunosuppressive medications.
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Background
Ipilimumab (Yervoy®) is approved by the Food and Drug
Administration (FDA) for the treatment of resected stage III
melanoma and advanced unresectable melanoma. It is a
fully human monoclonal antagonistic antibody which targets
cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells and
blocks the CTLA-4 interaction with its ligand CD80.
CTLA-4 is an immune check point molecule which down-
regulates pathways of T cell activation. Therefore, when
CTLA-4 is blocked with Ipilimumab, the T lymphocyte
inhibitory pathway is hindered, and the immune response
is enhanced, allowing T lymphocytes to destroy cancer
cells [1]. Melanoma incidence continues to rise and meta-
static melanoma results in approximately 53,000 deaths
per year worldwide as estimated by the World Health
Organization [2]. Ipilimumab was the first therapeutic
agent to demonstrate an overall survival benefit in the
treatment of advanced, unresectable melanoma [3]. It is
currently approved by the FDA at a dose of 3 mg/kg in
the metastatic setting. More recently, Ipilimumab 10 mg/
kg demonstrated an improved median relapse free survival
of 26.1 months compared to 17.1 months for placebo in
resected stage III cutaneous melanoma in the European
Organization for Research and Treatment of Cancer
(EORTC)18,071; this study led to its approval by the FDA
for this indication [4]. An update for this study was re-
cently published and reported a five year relapse free sur-
vival of 40.8% in the Ipilimumab group compared to
30.3% in the placebo group, with a median follow up of
5.3 years [5]. Five-year overall survival in the Ipilimumab
group was 65.4% versus 54.4% in the placebo group. No
vascular toxicities of any grade were reported. Please see
Table 1 for adverse events.
Preliminary safety data from an unplanned interim
analysis for Ipilimumab-treated subjects was recently
presented from the 1609 trial sponsored by the Eastern
Cooperative Oncology Group at the American Society for
Clinical Oncology [6]. This phase III study in subjects with
resected stage III and IV melanoma randomized 1673
patients to high dose interferon (HDI), Ipilimumab 3 mg/
kg, or Ipilimumab 10 mg/kg, with co-primary endpoints of
relapse free survival and overall survival. They reported
safety data for 1019 subjects treated at either dose of
Ipilimumab, as well as relapse free survival data for 773
concurrently randomized subjects with a median follow up
of 3.1 years. There were two deaths (0.4%) in the lower dose
Ipilimumab arm due to colitis and eight (1.6%) in the
* Correspondence: rithydpu@gmail.com; amritapa@med.umich.edu
1Division of Rheumatology, Department of Internal Medicine, University of
Michigan, Floor 3, Reception A, 1500 E Medical Center Drive, SPC 5342, Ann
Arbor, MI 48109, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Padda et al. Journal for ImmunoTherapy of Cancer  (2018) 6:12 
DOI 10.1186/s40425-018-0321-2
higher dose Ipilimumab arm: five subjects with colitis, one
pneumonitis, one thromboembolic event with hypophysitis,
and one cardiac event. This unplanned exploratory analysis
showed no difference in relapse free survival between the
low dose and high dose Ipilimumab, however additional
follow up is needed. Of note, the Ipilimumab 10 mg/kg
arm accrual was suspended for approximately 2 months
due to toxicity (Table 1). These adjuvant toxicity rates are
at least equivalent and possibly greater than those reported
in the advanced, unresectable melanoma setting with grade
3/4 rates reported at 27-58% for 10 mg/kg [7–10].
Case presentation
We report a case of a 52-year-old Caucasian woman who
was diagnosed with stage IIIB/C melanoma from a
regressed primary of the abdomen when she presented with
a bulky left groin mass. Imaging demonstrated a 6.5 cm
lobulated mass in the left groin involving soft tissue and
probable lymph nodes. Excisional biopsy revealed two
lymph nodes with metastatic melanoma; tumor cells were
positive for Melan-A and SOX-10, and negative for CD45,
Cytokeratin AE1/AE3. The patient reported a long standing
black skin lesion at the lower abdomen that had previously
grown and bled, but more recently had started to fade. This
lesion was biopsied and demonstrated superficial dermal
fibrosis with tumoral melanosis and pigment laden
macrophages (melanophages), consistent with a regressed
melanocytic lesion. She had no distant metastases on
staging and underwent a wide local excision of the
regressed primary site and radical resection of the
inguinal mass with complete lymph node dissection,
followed by reconstruction of the left groin with a
sartorius flap. Pathology of the 8.9 cm subcutaneous
mass revealed a spindle cell (sarcomatoid) melanoma
involving lymph node tissue, possible aggregate of
matted lymph nodes with extranodal extension, and
multiple additional lymph nodes without melanoma.
She had no known history of autoimmune conditions
or prior Raynaud’s phenomenon.
The first high dose Ipilimumab of 10 mg/kg was
administered at an outside hospital followed by limited
loose bowel movements and mouth soreness. One week
after the second Ipilimumab infusion (at 3-week intervals),
she developed myalgias, arthralgias, rash, vision changes,
jaw pain, and discoloration of several upper and lower limb
digits. Initially, the digital symptoms included intermittent
red and blue color changes, worse in the cold, and better
with warmth. Two weeks after the second infusion, her on-
cologist initiated Amlodipine 10 mg daily, Aspirin 81 mg
daily, and Prednisone 10 mg daily for suspected immune-
mediated Raynaud’s phenomenon. Serologic workup at the
initial presentation included a negative antinuclear
antibody, rheumatoid factor, anti-cyclic citrullinated pep-
tide antibody, cytoplasmic and perinuclear anti-neutrophil
cytoplasmic antibodies, cryoglobulins, and hepatitis C
antibody and ribonucleic acid (RNA); serum and urine
protein electrophoresis were within normal limits. She
reported immediate improvement of the myalgias, rash,
arthralgias and jaw pain, but she had progression of digital
pain and discoloration, therefore her oncologist adminis-
tered 500 mg of IV Methylprednisolone and increased her
daily Prednisone to 60 mg for a presumed Ipilimumab
immune related adverse event (IRAE). Her digits did not
improve, and she received a second 500 mg dose of IV
Table 1 Grade 3/4/5 toxicities from the E1609 trial and EORTC trial. These studies are in the setting of resected patients (adjuvant)
E1609 triala (Safety Data n = 1019)
(Total Enrollment = 1673)
EORTC 18071 trial (n = 945)
Treatment type Ipi 3 mg/kg Ipi 10 mg/kg Ipi 10 mg/kg Placebo
Number of patients 516 503 471 474
Adverse event of any grade 98.4% 100% (465 99%) 432 (91%)
Treatment-related AE (any grade) 96% 98.8%
Grade 3 adverse eventsb
37% 57%
Grade 4 adverse eventsb
Immune related adverse events (grade 3/4) 18.8% 34% 196 (41.6%) 13 (2.7%)
Gastrointestinal adverse eventb 12.0% 18.5% 76 (16%) 4 (< 1%)
Hepatic adverse eventsb 3.1% 7.8% 51 (11%) 1 (< 1%)
Endocrine adverse eventsb 6.6% 12.4% 37 (8%) 1(< 1%)
Neurologic adverse eventsb 2.0% 1.6% 9 (1.9%) 0 (0%)
Treatment related Adverse event leading to
discontinuation of treatment
35% 54% 240 (51%) 22(4.6%)
Death due to treatment related adverse events 2 (0.4%) 8 (1.6%) 5 (1.1%) 0
aAbstract available only for the E1609 trial
bGrade 3/4 adverse events
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Methylprednisolone three days later. The lower extremity
digital pain resolved, but the upper extremity digital
pain became so severe that she required high doses
of morphine.
She was admitted for inpatient management two days
after her outpatient steroid infusions. Physical exam revealed
acrocyanosis of all upper extremity digits (Fig. 1a & 1b). She
was initiated on 2 mg/kg of IV Methylprednisolone and
calcium channel blockade. Lower extremity digits were less
affected and demonstrated the greatest improvement. The
upper extremity digital pain and acrocyanosis persisted. She
was treated with one dose of 1000 mg of IV
Methylprednisolone with limited benefit, and thus
continued daily 2 mg/kg dosing. Arterial duplex dopplers
of upper and lower extremities were normal. Transthoracic
echocardiogram was negative for thrombus or mass.
Conventional angiogram was performed on the left upper
extremity; it revealed severely diminished blood flow in the
digital arteries beyond the proximal interphalangeal joints,
and the Verapamil challenge did not increase blood flow
(Fig. 2). Findings on the conventional angiogram were
consistent with small vessel occlusive disease. Extensive
autoantibody panels (inclusive of myeloperoxidase, protein-
ase 3, antinuclear, anti-centromere, anti-topoisomerase I,
Beta-2-glycoprotein 1, anti-cardiolipin, anti-neutrophil cyto-
plasmic) and viral panels (human immunodeficiency virus,
hepatitis panels) were negative. A full coagulopathy work-up
was unrevealing. Given concern for ongoing immune-
mediated vasculitis, the patient also received a 5-day course,
6-h per day, of Epoprostenol at a rate of 3 ng/kg/min. Fifty
units of botulinum toxin A in 10 mL of normal saline was
injected into each hand via palmar approach focusing on
the proximal aspect of each digital artery. After six days of
IV steroids, she was transitioned to oral Prednisone 100 mg
(1 mg/kg) daily. She received four cycles of Rituximab at
375 mg/m2, at approximately one-week intervals. Her
Prednisone was tapered to 10 mg daily over the course of
seven weeks. She then developed an IRAE of pneumonitis,
which quickly improved when the Prednisone was increased
to 50 mg daily. During steroid treatment, she was also on
Alendronate and calcium for osteoporosis prophylaxis,
Bactrim for pneumocystis pneumonia prophylaxis, and
Omeprazole for gastrointestinal protection.
After the four cycles of Rituximab, we believe that the
vasculitic process and additional damage were halted, as
she did not develop further proximal digital ischemia or
other systemic symptoms. The exam appeared worse
with dry gangrene of the fingertips, consistent with the
natural evolution of skin changes with distal digital
ischemia, as shown in Fig. 3a & b (Taken 5 weeks after
Fig. 1), likely reflecting consequences of the initial injury.
She did ultimately require distal digit amputations. See
Table 2 for the chronological outline of the case
presentation.
Discussion and conclusions
Immune related adverse events (IRAEs) are common
with checkpoint inhibitors, and can range from mild to
severe and life threatening [11, 12]. While there are
common patterns in presentation, it is not possible to
predict specific toxicities at this time. Skin, gastrointestinal
tract, liver and endocrine glands are commonly affected.
In general, IRAEs are treated with steroids which can
require high doses with slow tapers at least over one
Fig. 1 (Panel a and b). This picture was taken four weeks after her
second Ipilimumab infusion (week 26 on timeline). Physical exam
reveals acrocyanosis of all digits with small ulcers of the right
second and fourth fingertips
Fig. 2 Conventional angiogram of the left arm was performed five
weeks after her second Ipilimumab infusion (end of week 26 on
timeline). There is severely diminished flow in the digital arteries of
the left hand beyond the level of all proximal interphalangeal joints
(black arrow), consistent with small vessel occlusive disease
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month. Some IRAEs can be refractory and require
additional immunosuppressive or immune-modulating
agents including Infliximab or Mycophenolate [11–13].
Immune-related toxicities have been reported involving
nearly all organ systems, including rare cardiac and
neurologic toxicities [14]. Inflammatory arthritis mimick-
ing rheumatoid arthritis and sicca syndrome have
frequently been described in Ipilimumab use [15].
However, IRAEs involving blood vessels, such as vasculit-
ides are quite rare and reported at a less than 1%
incidence [16]. The most common vascular IRAE reported
to date is giant cell arteritis/temporal arteritis [17]. A
recent review addresses the molecular mechanism of how
immune checkpoint inhibitors increase anti-vascular
immunity risk, specifically in causing medium and large
cell vasculitis, like giant cell arteritis [18]. In a search
across PubMed, there have only been three case reports of
vasculitis in Ipilimumab use. One case was isolated
lymphocytic uterine vasculitis [19]. The other two cases
were polymyalgia rheumatica with giant cell arteritis, both
patients highly responsive to prednisone [20].
To our knowledge, this is the first reported case of an
Ipilimumab IRAE causing small vessel vasculitis manifest-
ing as digital ischemia. This case illustrates the current
debate in melanoma oncology regarding the risk-benefit
profile of adjuvant high dose Ipilimumab. Multiple studies
of programmed death receptor-1 inhibitors in the adjuvant
setting are completed with preliminary data or ongoing
with pending data and further data from ECOG 1609 trial
is forthcoming. This case highlights the importance of
close monitoring of patients on immune checkpoint inhibi-
tor therapy and prompt diagnosis and management of im-
mune related adverse events.
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Table 2 Summarized timeline of case presentation
Week 0 Presented with left groin mass. Excisional lymph node
biopsy was consistent with metastatic melanoma.
Week 4 Radical resection of melanoma with wide local excision of
regressed primary and complete lymph node dissection.
Week 19 First cycle of Ipilimumab 10 mg/kg. Side effects included
mild diarrhea and mouth soreness.
Week 22 Second cycle of Ipilimumab 10 mg/kg.
Week 23 Symptoms of myalgias, arthralgias, rash, vision changes,
jaw pain, and discoloration of several upper and lower
limb digits.
Week 24 Amlodipine 10 mg daily, Aspirin 81 mg daily, and
Prednisone 10 mg daily initiated for suspected Raynaud’s
phenomenon. Digital pain and discoloration progressed.
Week 25 She received Methylprednisolone 500 mg IV followed by
oral Prednisone 60 mg daily. Additional dose of 500 mg
Methylprednisolone IV given later in the week. Lower
extremity digital pain resolved, upper extremity digital
pain progressed.
Week 26 Admitted. Initiated on Methylprednisolone 2 mg/kg/day
IV, calcium channel blockade, and nitropaste.
Administered an additional Methylprednisolone 1000 mg
dose. Epoprostenol initiated for a 5-day course. Botulinum
toxin A was injected into each hand. Refer to Fig. 1 for
the physical exam and Fig. 2 for the conventional
angiogram.
Week 27 Transitioned to oral Prednisone 100 mg (1 mg/kg) daily
and Sildenafil 20 mg BID.
Week 27-30 Initiated on weekly Rituximab 375 mg/m2. Refer to Fig. 3
for the physical exam at week 31.
Week 32 Prednisone was tapered down to 10 mg daily.
Week 34 Developed IRAE of pneumonitis, prednisone was
increased to 50 mg daily and symptoms improved.
Week 48-52 Surgical amputation of multiple distal digits.
Week 49 Prednisone completely weaned off.
Fig. 3 (Panel a and b) This picture was taken nine weeks after her
second Ipilimumab infusion (week 31 on timeline). The patient is
status-post high dose steroids and four cycles of Rituximab. The exam
appeared worse with dry gangrene of the fingertips, secondary to the
natural evolution of skin changes with distal digital ischemia. We
believe that the vasculitic process was halted, as she did not develop
further proximal digital ischemia
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